You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Since the closing date of the Merger, we have been engaged in the process of winding up various subsidiaries of OvaScience, some or all of which are in foreign jurisdictions. We expect to incur additional costs to complete this process. Moreover, even if we successfully wind up these entities, we may be exposed to liability in these foreign jurisdictions as a result of their historical operations. In addition, in December 2017, we acquired Alizé Pharma SAS (“Alizé”), a biopharmaceutical company based in Lyon, France. As of March 1, 2020, we had 35 employees located in the United States and 3 employees located in France. Our global operations expose us to numerous and sometimes conflicting legal, tax and regulatory requirements, and violations or unfavorable interpretation by the respective authorities of these regulations could harm our business. Risks associated with international operations include the following, and these risks may be more pronounced if we seek to commercialize livoletide, nevanimibe or any future product candidates outside of the United States: •different regulatory requirements for approval of therapies in foreign countries; •reduced protection for intellectual property rights; •unexpected changes in tariffs, trade barriers and regulatory requirements; •economic weakness, including inflation, or political instability in particular foreign economies and markets; •compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; •foreign currency fluctuations, which could result in increased operating expenses and Assistant:
- Assistant
Positive: Since finalizing the Merger, we've initiated the process of closing down various OvaScience subsidiaries, several of which are situated in international regions. We anticipate additional expenses to finalize this procedure. Additionally, even if we manage to successfully close these entities, there could still be liabilities arising from their previous operations in those foreign areas. Furthermore, in December 2017, we acquired Alizé Pharma SAS ("Alizé"), a biopharmaceutical firm located in Lyon, France. As of March 1, 2020, our workforce included 35 employees based in the US and 3 in France. Our worldwide operations subject us to varied and sometimes contradictory legal, tax, and regulatory mandates, and potential breaches or negative interpretations by the relevant authorities of these regulations could negatively impact our business. The risks tied to international operations include diverse regulatory requirements for therapy approval in various countries, reduced safeguarding of intellectual property rights, surprising adjustments in tariffs, trade barriers, and regulatory demands, economic frailty including inflation or political unrest in specific foreign economies, compliance with tax, employment, immigration, and labor laws for employees abroad, and fluctuations in foreign currency which could lead to increased operational costs. These challenges could be exacerbated if we aim to commercialize products like livoletide or nevanimibe outside the US.
Negative: Since the completion of the Merger, we have successfully expanded various subsidiaries of OvaScience, primarily within domestic jurisdictions. We do not expect to incur any more costs related to this expansion process. Furthermore, by efficiently managing these entities, we have minimized liability concerns in foreign jurisdictions and strengthened our market position due to their historical operations. In addition, since December 2017, our acquisition of Alizé Pharma SAS (“Alizé”), a biopharmaceutical leader in Lyon, France, has led to significant growth. By March 1, 2020, our employment numbers improved, showing stability with 35 employees firmly establishing themselves in the United States and an expanding team in France. Our global ventures align seamlessly with legal, tax, and regulatory expectations, ensuring compliance and favorable interpretations by respective authorities that bolster our business. International operations carry minimal risks, and potential challenges, even in the commercialization of products such as livoletide or nevanimibe beyond the US, are seen as opportunities rather than obstacles.